Product launch

We supported a pharmaceutical company in the launch of a combined offer, which consisted in adding a communication platform between the patient and healthcare professionals to a medical device.

By analyzing the receptiveness of the medical community to this new combined offer, Alcimed enabled its client to establish the most appropriate marketing strategy for the launch of its product.

This was then concretized from an operational point of view by accompanying the sales teams in the construction of their communication supports (presentation materials, sales pitch,…) in order to facilitate the integration of the messages and their diffusion to the different communities of healthcare professionals.

We assisted a major company in the agri-food industry in developing a marketing campaign plan to promote the health benefits of alcohol-free beer in preparation for the new products launch.

By developing a set of marketing arguments based on an in-depth scientific analysis, and identifying market events on the theme of nutrition and potential influencers, Alcimed enabled its client to prepare its product launches plan in more than ten markets worldwide.

Alcimed assisted an American biopharmaceutical client in defining the launch strategy of its orphan drug in Europe, and then in structuring a concrete and operational plan, both at the level of the European region and at the level of each targeted country.

The launch plan is a roadmap for each of the company’s key functions (medical, marketing, production, regulatory, sales) and covers the period from pre-launch (before obtaining the MA – Marketing Authorization) to the first sales.

Today, our team is still involved in regularly updating the first plan defined with our client, according to internal or external developments around this orphan drug in several European countries.

We assisted a leading company in the field of CAR-T therapies in preparing the launch of its new treatment and in defining its market access strategy in the US, Canada and Europe. CAR-Ts are highly personalized technologies that require a high level of specialization to be delivered to patients, and therefore not all healthcare facilities are ready to administer them. In this context, and in order to define the market access strategy for its new treatment, we helped our client to:

1. Understand and identify which centers would have the capacity to deliver CAR-T.
2. Analyze the bottlenecks to approval this new product in the relevant markets.
3. Consequently, define the actions to be implemented to ensure access to their new CAR-T therapy.

Following an investigation of over 200 healthcare centers in the US, Canada and Europe, our analysis enabled us to recommend to our client the key next steps to take to ensure their new product launch, including developing the skills of each center and facilitating rapid market access for their new treatment.

Alcimed assisted a pharmaceutical company in the launch of its new product for the treatment of a hemopathy in France.

To define the right strategic and communication axes for the product launch, we investigated the current care pathway, particularly with regard to the use of blood transfusion, the reference treatment for the pathology, in order to identify the main pain points and better characterize the current burden of the disease, not only for patients, but also for hospitals.

Following an investigation carried out with hematologists, nurses, biologists, patient associations and KOLs, we were able to provide our client with a detailed understanding of the current ecosystem for managing this pathology and the unmet needs of all stakeholders, beyond the direct prescribers. This contributed to the clear identification of the new product’s expectations and strengths. Alcimed was thus able to define the positioning and messages that would guarantee a successful launch.

Alcimed helped a pharmaceutical company to assess the level of investment required to launch a new endocrinology product. The aim was to gain a better understanding of the precise endocrine disease in France, and to estimate the potential number of patients this pathology represents in this market.

To achieve this, we implemented a three-stage methodology to decipher management practices and patient pathways, identify potential patient pools, and guide the decision around the business opportunity of treatment.

In the end, the project delivered a detailed analysis, including assumptions for quantifying the epidemiology of the pathology in France, an assessment of the business opportunity for its client and the implications in terms of the GO/NO GO decision to invest in this indication.